CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Attention Bias Modification (ABM)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug380 Blood sample for serological test Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial

The outbreak of the 2019 Coronavirus (COVID-19) pandemic is a major stressor leading to increased levels of anxiety, and specifically, an excessive fear of being infected and affected by the disease among major parts of the population. At the same time, the access to mental health services is limited due to the lockdown policy applied in many countries worldwide, warranting the development of home-delivered interventions aimed at reducing stress and anxiety symptoms. Attention Bias modification (ABM) has been found to be an efficacious computerized intervention to reduce anxiety symptoms. In this open pilot trial, participants reporting on elevated levels of health anxiety concerning the COVID-19 epidemic will receive one session of ABM over 5 consecutive days (5 sessions total). Symptoms of health anxiety, state anxiety, generalized anxiety, and depression will be measured at baseline and post-treatment.

NCT04365972 Anxiety Behavioral: Attention Bias Modification (ABM)
MeSH:Anxiety Disorders

Primary Outcomes

Description: The COVID-19 anxiety inventory is a self-report questionnaire screening for concerns and fears regarding COVID-19 contagion. The Inventory consists of 6 items. Scores can range from 6 to 30, with higher scores denoting higher symptom severity.

Measure: Change from baseline of the total score of a novel COVID-19 anxiety inventory

Time: up to 2 days pre-treatment and 1-2 days post-treatment

Secondary Outcomes

Description: The Health Anxiety Inventory (HAI) is a validated self-report measure assessing health anxiety. Total score can range from 0 to 42, with higher scores denoting higher symptom severity

Measure: Change from baseline of the total score of the Health Anxiety Inventory

Time: up to 2 days pre-treatment and 1-2 days post-treatment

Description: The State Anxiety Inventory is a validated self-report measure for state anxiety. Total score can range from 20 to 80, with higher scores denoting higher levels of state anxiety.

Measure: Change from baseline of the total score of the State Anxiety Inventory

Time: up to 2 days pre-treatment and 1-2 days post-treatment

Description: The PHQ-9 is a 9-item self-report scale for depression symptoms. Scores can range from 0 to 27, with higher scores reflecting more symptoms of depression.

Measure: Change from Baseline of the total score of the PHQ-9

Time: up to 2 days pre-treatment and 1-2 days post-treatment

Description: The GAD-7 is a 7-item self-report scale for generalized anxiety symptoms. Scores can range from 0 to 21, with higher scores reflecting more symptoms of generalized anxiety.

Measure: Change from Baseline of the total score of the GAD-7

Time: up to 2 days pre-treatment and 1-2 days post-treatment


No related HPO nodes (Using clinical trials)